GENEVA: The World Health Organization granted emergency validation to the Pfizer-BioNTech vaccine, paving the way for countries worldwide to quickly approve its import and distribution.
Britain launched its inoculation drive with the US-German vaccine on December 8, followed by the United States, Canada, and European Union countries.
WHO said the Pfizer-BioNTech vaccine was the first to receive its “emergency validation” since the novel coronavirus first broke out in China a year ago. “This is a very positive step towards ensuring global access to COVID-19 vaccines,” said Mariangela Simao, a top WHO official tasked with ensuring access to medicines.
“But I want to emphasise the need for an even greater global effort to achieve enough vaccine supply to meet the needs of priority populations everywhere,” she said in a statement.
WHO said its validation of the vaccine “opens the door for countries to expedite their own regulatory approval processes to import and administer the vaccine”.
WHO said its emergency use listing opens the way for regulators in different countries to approve the import and distribution of the vaccine. It said it also enables UNICEF, which plays a key logistical role in distributing anti-Covid vaccines, and the Pan-American Health Organization to procure the vaccine for countries that need it.
WHO convened its own experts and those from around the world to review the data on the Pfizer-BioNTech vaccine’s “safety, efficacy and quality,” weighing the benefits against the risks.
“The review found that the vaccine met the must-have criteria for safety and efficacy set out by WHO, and that the benefits of using the vaccine to address COVID-19 offset potential risks,” it said.
WHO said the Pfizer-BioNTech vaccine met its safety requirements and its benefits outweighed any potential risks. The vaccine, which must be kept at ultra-low temperatures, is already being administered in several countries, including the United States, Canada, Qatar, Bahrain and Mexico.
